This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (236)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Immunologic Disorders  • Review  • Rheumatoid Arthritis  • Adverse Effects  • Alert me on articles by topic

Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials

Tim Bongartz, MD; Alex J. Sutton, PhD; Michael J. Sweeting, MSc; Iain Buchan, MD, MFPH; Eric L. Matteson, MD, MPH; Victor Montori, MD, MSc

JAMA. 2006;295:2275-2285.

Context  Tumor necrosis factor (TNF) plays an important role in host defense and tumor growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious infections and malignancies.

Objective  To assess the extent to which anti-TNF antibody therapies may increase the risk of serious infections and malignancies in patients with rheumatoid arthritis by performing a meta-analysis to derive estimates of sparse harmful events occurring in randomized trials of anti-TNF therapy.

Data Sources  A systematic literature search of EMBASE, MEDLINE, Cochrane Library, and electronic abstract databases of the annual scientific meetings of both the European League Against Rheumatism and the American College of Rheumatology was conducted through December 2005. This search was complemented with interviews of the manufacturers of the 2 licensed anti-TNF antibodies.

Study Selection  We included randomized, placebo-controlled trials of the 2 licensed anti-TNF antibodies (infliximab and adalimumab) used for 12 weeks or more in patients with rheumatoid arthritis. Nine trials met our inclusion criteria, including 3493 patients who received anti-TNF antibody treatment and 1512 patients who received placebo.

Data Extraction  Data on study characteristics to assess study quality and intention-to-treat data for serious infections and malignancies were abstracted. Published information from the trials was supplemented by direct contact between principal investigators and industry sponsors.

Data Synthesis  We calculated a pooled odds ratio (Mantel-Haenszel methods with a continuity correction designed for sparse data) for malignancies and serious infections (infection that requires antimicrobial therapy and/or hospitalization) in anti-TNF–treated patients vs placebo patients. We estimated effects for high and low doses separately. The pooled odds ratio for malignancy was 3.3 (95% confidence interval [CI], 1.2-9.1) and for serious infection was 2.0 (95% CI, 1.3-3.1). Malignancies were significantly more common in patients treated with higher doses compared with patients who received lower doses of anti-TNF antibodies. For patients treated with anti-TNF antibodies in the included trials, the number needed to harm was 154 (95% CI, 91-500) for 1 additional malignancy within a treatment period of 6 to 12 months. For serious infections, the number needed to harm was 59 (95% CI, 39-125) within a treatment period of 3 to 12 months.

Conclusions  There is evidence of an increased risk of serious infections and a dose-dependent increased risk of malignancies in patients with rheumatoid arthritis treated with anti-TNF antibody therapy. The formal meta-analysis with pooled sparse adverse events data from randomized controlled trials serves as a tool to assess harmful drug effects.

Author Affiliations: Division of Rheumatology and Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn (Drs Bongartz and Matteson); Department of Health Sciences, University of Leicester, Leicester, England (Dr Sutton); MRC Biostatistics Unit, Institute of Public Health, Cambridge, England (Mr Sweeting); Northwest Institute for Bio-Health Informatics, University of Manchester, Manchester, England (Dr Buchan); Knowledge and Encounter Research Unit and Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn (Dr Montori).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum
Carter et al.
Ann Rheum Dis 2008;67:1181-1183.
ABSTRACT | FULL TEXT  

Resolution of Non-Small-Cell Lung Cancer after Withdrawal of Anti-TNF Therapy
Lees et al.
NEJM 2008;359:320-321.
FULL TEXT  

Review: Efficacy and safety of adalimumab in Crohn's disease
Lichtenstein et al.
Therapeutic Advances in Gastroenterology 2008;1:43-50.
ABSTRACT  

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-{alpha} inhibitor, in patients with advanced cancer
Brown et al.
Ann Oncol 2008;19:1340-1346.
ABSTRACT | FULL TEXT  

What potential biologic treatments are available for osteolysis?
Schwarz
J Am Acad Orthop Surg 2008;16:S72-S75.
ABSTRACT | FULL TEXT  

Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial
Judson et al.
Eur Respir J 2008;31:1189-1196.
ABSTRACT | FULL TEXT  

ADAM-17 predicts adverse outcome in patients with breast cancer
McGowan et al.
Ann Oncol 2008;19:1075-1081.
ABSTRACT | FULL TEXT  

Medical management of Crohn's disease
Cummings et al.
BMJ 2008;336:1062-1066.
FULL TEXT  

Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis
Choy et al.
Ann Rheum Dis 2008;67:656-663.
ABSTRACT | FULL TEXT  

A Pilot Study on Ocular Safety of Intravitreal Infliximab in a Rabbit Model
Giansanti et al.
IOVS 2008;49:1151-1156.
ABSTRACT | FULL TEXT  

Sepsis: rethinking the approach to clinical research
Marshall
J. Leukoc. Biol. 2008;83:471-482.
ABSTRACT | FULL TEXT  

Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon {gamma} assay
Matulis et al.
Ann Rheum Dis 2008;67:84-90.
ABSTRACT | FULL TEXT  

Treatment targets in renal fibrosis
Boor et al.
Nephrol Dial Transplant 2007;22:3391-3407.
FULL TEXT  

Level of Agreement With the British Guidelines for the Use of Biological Therapies for Psoriasis
Nijsten
Arch Dermatol 2007;143:1567-1569.
FULL TEXT  

Isolated knee monoarthritis heralding resectable non-small-cell lung cancer. A paraneoplastic syndrome not previously described
Cantini et al.
Ann Rheum Dis 2007;66:1672-1674.
ABSTRACT | FULL TEXT  

Successful Intravenous Regional Block with Low-Dose Tumor Necrosis Factor-{alpha} Antibody Infliximab for Treatment of Complex Regional Pain Syndrome 1
Bernateck et al.
Anesth. Analg. 2007;105:1148-1151.
ABSTRACT | FULL TEXT  

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
Askling et al.
Ann Rheum Dis 2007;66:1339-1344.
ABSTRACT | FULL TEXT  

Skin cancer in psoriatic arthritis treated with anti-TNF therapy
Sheppard et al.
Rheumatology (Oxford) 2007;46:1622-1623.
FULL TEXT  

Increased Glioma Growth in Mice Depleted of Macrophages
Galarneau et al.
Cancer Res. 2007;67:8874-8881.
ABSTRACT | FULL TEXT  

Letter To the Editor: Infliximab-induced SLE-like syndrome involving the lung and pleura
Nugent et al.
Lupus 2007;16:764-766.
 

Rapid and Deep Control of Inflammation in Rheumatoid Arthritis with Infliximab and Its Correlation with Acute-Phase Reactants
SCALI et al.
Ann. N. Y. Acad. Sci. 2007;1110:389-401.
ABSTRACT | FULL TEXT  

Infliximab as a Therapy for Idiopathic Hypereosinophilic Syndrome
Taverna et al.
Arch Dermatol 2007;143:1110-1112.
FULL TEXT  

Psoralen and Ultraviolet A Light Therapy for Psoriasis
Stern
NEJM 2007;357:682-690.
FULL TEXT  

Narrowband UV-B Phototherapy, Alefacept, and Clearance of Psoriasis
Legat et al.
Arch Dermatol 2007;143:1016-1022.
ABSTRACT | FULL TEXT  

Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection
Zalevsky et al.
J. Immunol. 2007;179:1872-1883.
ABSTRACT | FULL TEXT  

The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy
Loberg et al.
CA Cancer J Clin 2007;57:225-241.
ABSTRACT | FULL TEXT  

Use of Biological Agents in Patients With Moderate to Severe Psoriasis: A Cohort-Based Perspective
Jones-Caballero et al.
Arch Dermatol 2007;143:846-850.
ABSTRACT | FULL TEXT  

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
Carmona et al.
Ann Rheum Dis 2007;66:880-885.
ABSTRACT | FULL TEXT  

Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis
Bernatsky et al.
Rheumatology (Oxford) 2007;46:1157-1160.
ABSTRACT | FULL TEXT  

Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial
Sandborn et al.
ANN INTERN MED 2007;146:829-838.
ABSTRACT | FULL TEXT  

Humoral and Cellular Monitoring to Predict the Development of Infection in Crohn's Disease Patients Beginning Treatment with Infliximab
CARBONE et al.
Ann. N. Y. Acad. Sci. 2007;1107:346-355.
ABSTRACT | FULL TEXT  

Risks and benefits of biologic therapy for inflammatory bowel diseases
D'Haens
Gut 2007;56:725-732.
FULL TEXT  

Unexpected Failure of Anti-Tumor Necrosis Factor Therapy in Chronic Obstructive Pulmonary Disease
Barnes
Am. J. Respir. Crit. Care Med. 2007;175:866-867.
FULL TEXT  

Non-Hodgkin's lymphoma--meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories
Bernatsky et al.
Rheumatology (Oxford) 2007;46:690-694.
ABSTRACT | FULL TEXT  

Parapharyngeal Abscess in a Patient Receiving Etanercept
Borras-Blasco et al.
The Annals of Pharmacotherapy 2007;41:341-344.
ABSTRACT | FULL TEXT  

Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study
Capell et al.
Ann Rheum Dis 2007;66:235-241.
ABSTRACT | FULL TEXT  

Lymphoma and rheumatoid arthritis--again
Symmons
Rheumatology (Oxford) 2007;46:1-2.
FULL TEXT  

Treatment of rheumatoid arthritis
Gaffo et al.
Am J Health Syst Pharm 2006;63:2451-2465.
ABSTRACT | FULL TEXT  

ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2006;11:190-190.
FULL TEXT  

A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents.
Ritchlin and Tausk
Ann Rheum Dis 2006;65:1541-1544.
FULL TEXT  

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Costenbader et al.
JAMA 2006;296:2201-2201.
FULL TEXT  

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Callegari et al.
JAMA 2006;296:2202-2202.
FULL TEXT  

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Hochman and Wolff
JAMA 2006;296:2203-2203.
FULL TEXT  

Investigation, explanation, and apology for incomplete and erroneous disclosures.
Matteson and Bongartz
JAMA 2006;296:2205-2205.
FULL TEXT  

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Okada and Siegel
JAMA 2006;296:2201-2202.
FULL TEXT  

Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics.
Smedby et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:2069-2077.
ABSTRACT | FULL TEXT  

Use of biologics in rheumatoid arthritis: Where are we going?
Pucino et al.
Am J Health Syst Pharm 2006;63:S19-S41.
ABSTRACT | FULL TEXT  

Infliximab (Remicade)
JWatch Pediatrics 2006;2006:3-3.
FULL TEXT  

Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis.
Scott and Kingsley
NEJM 2006;355:704-712.
FULL TEXT  

Biology of CCR5 and its role in HIV infection and treatment.
Lederman et al.
JAMA 2006;296:815-826.
ABSTRACT | FULL TEXT  

Anti-TNF Antibody Therapies -- How Safe?
JWatch Women's Health 2006;2006:7-7.
FULL TEXT  

Update on Risk for Infection and Malignancy with Anti-TNF Antibody Therapy
Journal Watch Dermatology 2006;2006:3-3.
FULL TEXT  

What's new in the other general journals.
Tonks
BMJ 2006;332:1264-1265.
FULL TEXT